Deep Dive: Digital Health 2019Digital is now ubiquitous, but for every piece of revolutionary tech there are dozens of passing fads that Share XDeep Dive: Digital Health 2019https://pharmaphorum.com/views-and-analysis/deep-dive-digital-health-2019/
The best-selling drugs of the next 5 yearsMerck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in Share XThe best-selling drugs of the next 5 yearshttps://pharmaphorum.com/views-analysis-sales-marketing/the-best-selling-drugs-of-the-next-5-years/
Searching for new hope in Alzheimer’sFor the best part of two decades, it seemed as if pharma hit a brick wall as it Share XSearching for new hope in Alzheimer’shttps://pharmaphorum.com/r-d/views-analysis-r-d/searching-for-new-hope-in-alzheimers/
Pharma’s reputation problem goes beyond pricing – people don’t know what it stands forMatthew Hare-Scott argues that renewed attacks on the industry from politicians have much to do with pharma losing Share XPharma’s reputation problem goes beyond pricing – people don’t know what it stands forhttps://pharmaphorum.com/views-and-analysis/pharmas-reputation-problem-goes-beyond-pricing-people-dont-know-what-it-stands-for/
Q&A: Albireo’s Ron Cooper on bile acid modulationWhile bile acids might not be as trendy as gene editing, modulating them has potential for first-in-class therapies Share XQ&A: Albireo’s Ron Cooper on bile acid modulationhttps://pharmaphorum.com/r-d/views-analysis-r-d/qa-albireos-ron-cooper-on-bile-acid-modulation/
Personalised digital health: A tool, not a silver bulletDigital health tech has the potential to help us all live longer, healthier lives – but it isn’t Share XPersonalised digital health: A tool, not a silver bullethttps://pharmaphorum.com/digital/personalised-digital-health-a-tool-not-a-silver-bullet/
Nice numbers at 20: what end-of-life evidence does NICE draw on?NICE may be 20 this year, but its policy on end-of-life (EoL) treatments – where NICE can recommend Share XNice numbers at 20: what end-of-life evidence does NICE draw on?https://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-what-end-of-life-evidence-does-nice-draw-on/
eyeforpharma Patient Summit Europe roundupeyeforpharma’s Patient Summit Europe brought together leading patient innovators from industry and patient associations for two days of Share Xeyeforpharma Patient Summit Europe rounduphttps://pharmaphorum.com/views-analysis-patients/eyeforpharma-patient-summit-europe-roundup/
Getting MS diagnosis rightMS advocate Trishna Bharadia explains how diagnosis needs to change and why pharma shouldn’t be using the word Share XGetting MS diagnosis righthttps://pharmaphorum.com/views-analysis-patients/getting-ms-diagnosis-right/
